The conversation discusses the complexity of hair loss causes, suggesting that DHT sensitivity alone doesn't fully explain it. Treatments mentioned include finasteride and dutasteride.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
Androgenetic alopecia is caused by DHT affecting hair growth. Finasteride and minoxidil are used to manage hair loss by blocking DHT and promoting hair growth.
Minoxidil can regrow hair but doesn't address the underlying issue of DHT, leading to continued hair loss. Users discuss their experiences with finasteride and dutasteride, mentioning side effects, personal outcomes, and alternatives like microdosing topical finasteride.
Vitamin C mixed with shampoo stopped shedding and promoted hair regrowth after 1.5 years. Both the person and their wife experienced significant hair loss reduction with this method.
Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgenreceptors in the scalp.
Finasteride significantly increased testosterone levels for the user, with no major side effects except watery semen, which was resolved with zinc supplements. The user's hairline stopped receding and slightly improved.
A user experienced puffy nipples and lumps from finasteride, leading to a dilemma between continuing treatment with potential surgery or accepting hair loss. They restarted finasteride at a lower dose with supplements but still face side effects and are seeking advice on whether to persist or stop.
Quitting vaping significantly reduced hair loss for a user who was a heavy vaper and also taking finasteride. Some participants suggest nicotine's vasoconstrictive properties may worsen hair loss, while others share personal anecdotes of hair improvement after quitting smoking or vaping.
A user's experience with microneedling monotherapy and potential treatments such as finasteride, minoxidil, Stemoxydine, rosemary oil, peppermint oil, and RU58841 for reversing hair loss.
The conversation discusses hair loss treatments, focusing on the use of topical minoxidil, microneedling, finasteride, and dutasteride, while debating the role of testosterone and DHT in hair loss. It also touches on the potential liver health impacts of these treatments and the genetic sensitivity of hair follicles to androgens.
RU and Pyri block androgenreceptors to prevent hair loss but may also hinder hair regrowth since they prevent testosterone, which can stimulate hair growth, from binding to these receptors. The user is questioning if this understanding is correct.
Fluridil may decrease the number of androgenreceptors in hair follicles by up to 95%. This suggests a different action mechanism from other non-steroidal antiandrogens like RU58841, indicating they might be used together.
The efficacy of degrading the androgenreceptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.
Researching and developing an effective local antagonist to block the androgenreceptors for hair loss, as opposed to using DHT synthesis inhibitors that lower serum DHT levels. Several treatments such as CosmeRNA and Pyrilutamide are currently in development or undergoing trials.
The relative strength of Pyrilutamide compared to RU58841 in terms of androgenreceptor binding affinity. It has been noted that Pyrilutamide is 4x stronger than RU58841, with a higher binding affinity than DHT itself.
The conversation discusses androgenreceptor degraders for hair loss, highlighting their potential advantages over traditional AR blockers like RU58841 and pyrilutamide. Concerns about the safety and cost of these treatments are also mentioned.
The post is about whether there is any additional benefit to using alfatradiol or other estrogen treatments for hair loss if someone is already using finasteride, dutasteride, or an androgenreceptor inhibitor like RU58841, pyrithione zinc, or fluridil.
The conversation discusses the effectiveness of reducing DHT for hair loss treatment and explores alternative approaches like reducing androgenreceptor sensitivity. Specific treatments mentioned include finasteride, dutasteride, pyrilutamide (KX-826), GT20029, and RU58841.
GT20029 and CosmeRNA are both potential hair loss treatments; GT20029 breaks down the androgenreceptor, while CosmeRNA prevents its production. Continuous use is needed, but less frequently than current treatments like Minoxidil and Finasteride.
The post discusses using 2% ketoconazole shampoo as a competitive androgenreceptor antagonist for hair loss, applied for 1.5 hours daily. The user questions its effectiveness and potential benefits compared to finasteride and minoxidil.
The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgenreceptor degrader for hair loss, and whether it can fully degrade androgenreceptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.
The GT20029 tincture, a topical androgenreceptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
Hopeful treatments for hair loss, including Verteporfin, AndrogenReceptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.
A user is experiencing continued hair loss despite using 0.5mg dutasteride and 2.5mg minoxidil, and is seeking advice on why the treatments aren't working and how to address potential androgenreceptor sensitivity. Replies suggest getting tested and considering scalp micropigmentation (SMP).
The conversation discusses doubts about the effectiveness of topical finasteride for hair loss, suggesting that DHT could be produced elsewhere in the body and affect the scalp. It proposes that androgenreceptor antagonists like spironolactone and clascoterone might be more effective as they could prevent this potential bypass mechanism.
Pyrilutamide is believed to be more effective than RU58841 and 1 mg finasteride in treating hair loss, with no systemic hormonal effects and the potential to block more than 31% of scalp DHT. It may also antagonize scalp testosterone due to its action as an androgenreceptor antagonist.